Last reviewed · How we verify

NCT05795712: COPDnoICS

'Real Life' Monitoring of COPD no ICS Patients

Completed Last updated 3 April 2023
What this trial tests

trial testing Therapy Change from Baseline in COPD in 53 participants. Completed in 9 March 2023.

Timeline
28 June 2017
Primary endpoint
7 September 2020
9 March 2023

Quick facts

Lead sponsorIstituti Clinici Scientifici Maugeri SpA
StatusCompleted
Study typeOBSERVATIONAL
Enrollment53
Start date28 June 2017
Primary completion7 September 2020
Estimated completion9 March 2023
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Istituti Clinici Scientifici Maugeri SpA

Who can join

Adults 18 to 85, any sex, with COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study will be to assess in patients with mild-to-moderate COPD the role of inflammation in the patient's therapeutic management and follow-up.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up.
    Pignatti P, Visca D, Zappa M, Zampogna E, et al · · 2024 · cited 3× · PMID 38764008 · DOI 10.1186/s12890-024-03062-1

Verify or expand the search:

Other recruiting trials for COPD

Currently open trials in the same condition.

Other Istituti Clinici Scientifici Maugeri SpA trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05795712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing